Baseline and myocardial infarction–related characteristics
| Characteristic | Group; no. (%) of patients* | |
|---|---|---|
| Placebo n = 42 | G-CSF n = 42 | |
| Age, yr, mean ± SD | 57.0 ± 9.2 | 53.3 ± 8.7 |
| Sex, male | 34 (81) | 35 (83) |
| Concurrent conditions | ||
| Hypertension | 16 (38) | 14 (33) |
| Diabetes mellitus | 6 (14) | 12 (29) |
| Dyslipidemia | 7 (17) | 10 (24) |
| Smoking | 22 (52) | 14 (33) |
| Cardiovascular history | ||
| Myocardial infarction | 6 (14) | 5 (12) |
| PCI | 4 (10) | 0 (0) |
| Stroke | 0 (0) | 1 (2) |
| Killip class | ||
| I or II | 40 (95) | 40 (95) |
| III or IV | 2 (5) | 3 (7) |
| Creatinine, “mol/L, mean ± SD | 89.6 ± 21.7 | 90.5 ± 25.7 |
| Peak creatinine kinase, units/L, median (IQR) | 2932 (1890–4769) | 3180 (1610–4701) |
| Revascularization | ||
| Pharmacoinvasive | 8 (19) | 12 (29) |
| Primary PCI | 34 (81) | 31 (74) |
| Symptom onset to presentation, min, median (IQR) | 360 (60–1440) | 150 (60–735) |
| Presentation to reperfusion therapy, min, median (IQR) | 60 (55–90) | 60 (60–90) |
| TIMI flow before PCI | ||
| 0 | 27 (64) | 23 (55) |
| 1 | 3 (7) | 5 (12) |
| 2 | 4 (10) | 7 (17) |
| 3 | 8 (19) | 8 (19) |
| TIMI flow after PCI | ||
| 0 | 2 (5) | 0 (0) |
| 1 | 0 (0) | 0 (0) |
| 2 | 1 (2) | 2 (5) |
| 3 | 39 (93) | 41 (98) |
| Discharge medications | ||
| Acetylsalicylic acid | 42 (100) | 42 (100) |
| Clopidogrel | 42 (100) | 42 (100) |
| Warfarin | 14 (33) | 21 (50) |
| β-Blocker | 42 (100) | 42 (100) |
| ACE inhibitor/ARB | 41 (98) | 41 (98) |
| Statin | 42 (100) | 42 (100) |
Note: ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, G-CSF = granulocyte colony-stimulating factor, IQR = interquartile range, PCI = percutaneous coronary intervention, SD = standard deviation, TIMI = thrombolysis in myocardial infarction.
↵* Unless otherwise stated.